Long-Acting β2-Agonists in the Treatment of Acute Exacerbations of COPD

被引：0
|
作者：
Mario Cazzola
Maria G. Matera
Maria D’Amato
Paolo Noschese
Clara Califano
Felice Di Perna
Claudio Terzano
Gennaro D’Amato
机构：
[1] Ospedale A. Cardarelli,Unità Complessa di Pneumologia ed Allergologia, Dipartimento di Pneumologia
[2] Facoltà di Medicina e Chirurgia,Unità di Farmacologia, Dipartimento di Medicina Sperimentale
[3] Seconda Università Napoletana,Dipartimento di Scienze Cardiotoraciche e Respiratorie, Facoltà di Medicina e Chirurgia
[4] Seconda Università Napoletana,Dipartimento di Scienze Cardiovascolari e Respiratorie
[5] Università ‘La Sapienza’,undefined
来源：
Clinical Drug Investigation | 2002年 / 22卷
关键词：
Chronic Obstructive Pulmonary Disease; Salbutamol; Force Vital Capacity; Acute Exacerbation; Fluticasone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To evaluate the acute bronchodilating effect of cumulative doses of formoterol administered via Turbuhaler™ or salmeterol administered via pressurised metered-dose inhaler (pMDI) in patients with mild acute exacerbations of chronic obstructive pulmonary disease (COPD) to determine if these drugs might be used in this condition.
引用
收藏
页码：369 / 376
页数：7
相关论文
共 50 条
  • [1] Long-acting β2-agonists in the treatment of acute exacerbations of COPD
    Cazzola, M
    Matera, MG
    D'Amato, M
    Noschese, P
    Califano, C
    Di Perna, F
    Terzano, C
    D'Amato, G
    CLINICAL DRUG INVESTIGATION, 2002, 22 (06) : 369 - 376
  • [2] Long-acting β2 agonists as potential option in the treatment of acute exacerbations of COPD
    Cazzola, M
    Matera, MG
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2003, 16 (04) : 197 - 201
  • [3] Long-acting β2-agonists in the management of asthma exacerbations
    Hospenthal, MAC
    Peters, JI
    CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (01) : 69 - 73
  • [4] Long-acting inhaled β2-agonists for stable COPD
    Dougherty, JA
    Didur, BL
    Aboussouan, LS
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (09) : 1247 - 1255
  • [5] The clinical role of long-acting β2-agonists in COPD
    Kips, J
    RESPIRATORY MEDICINE, 2000, 94 : S1 - S5
  • [6] Benefits of long-acting β2-agonists
    Lipworth, Brian J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (03) : 725 - 725
  • [7] Pharmacogenomics of long-acting β2-agonists
    Blake, Kathryn
    Lima, John
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (11) : 1733 - 1751
  • [8] New long-acting β2-agonists
    不详
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (09) : 1385 - 1388
  • [9] Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history
    Bateman, E. D.
    Rabe, K. F.
    Calverley, P. M. A.
    Goehring, U. M.
    Brose, M.
    Bredenbroeker, D.
    Fabbri, L. M.
    EUROPEAN RESPIRATORY JOURNAL, 2011, 38 (03) : 553 - 560
  • [10] Advances in asthma and COPD treatment:: Combination therapy with inhaled corticosteroids and long-acting β2-agonists
    Miller-Larsson, A.
    Selroos, O.
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (25) : 3261 - 3279
12345